Imunon Inc Dossier - Source-backed chat

Imunon Inc

IMNNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.64

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.32Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $7.4M

Enterprise Value $1.5M

Shares Outstanding 6.1M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Imunon, Inc. is a clinical-stage biotechnology company advancing a highly promising DNA-mediated immunotherapy pipeline. The company's lead candidate, IMNN-001 (formerly GEN-1), is currently in a pivotal Phase 3 trial (OVATION 3) for newly diagnosed advanced ovarian cancer. This program is backed by remarkable Phase 2 (OVATION 2) final data showing a median overall survival (OS) benefit of 14.7 months over standard of care, which increases to 24.2 months when combined with PARP inhibitors. While Imunon is pre-revenue and faces significant liquidity constraints with a cash balance of $4.8 million as of March 31, 2026, its strategic reorganization in early 2026 has streamlined operations to focus resources on OVATION 3. The stock offers an asymmetric risk-reward profile with substantial upside potential if Phase 3 milestones are achieved.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$17.00

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

OVATION 3 trial enrollment slows down, or interim analyses fail to show a clear survival benefit, delaying the path to a BLA filing. Severe liquidity constraints force highly dilutive equity financings at depressed valuations, significantly eroding shareholder value. The company fails to secure strategic partnerships, limiting its ability to advance its preclinical pipeline (IP-Y, IMNN-201).

Base CaseCentral scenario

$10.0055%

OVATION 3 enrollment continues ahead of schedule, with steady progress toward the Q1 2029 completion target. The company successfully manages its cash runway through disciplined spending and tactical ATM usage or structured non-dilutive financing. Wall Street analysts maintain a consensus price target of $10.00 to $17.00, reflecting strong clinical proof-of-concept and aligned regulatory pathways with the FDA.

Bull CaseUpside scenario

$29.0025%

The pivotal Phase 3 OVATION 3 trial meets its primary endpoints early during interim analyses, leading to an accelerated BLA filing and approval in the HRD+ ovarian cancer population. Imunon secures a lucrative global co-development partnership, resolving its cash runway concerns without diluting shareholders. The PlaCCine platform (IMNN-101) achieves clinical validation, opening up multi-billion dollar infectious disease vaccine markets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Unprecedented Phase 2 overall survival benefit of 14.7 months (and up to 24.2 months with PARP inhibitors) in advanced ovarian cancer.
FDA-aligned Phase 3 protocol for OVATION 3, providing a clear and validated regulatory path to a BLA filing.
Proprietary TheraPlas and PlaCCine platforms offer broad applicability across oncology and infectious diseases.
Strategic reorganization in early 2026 successfully reduced non-essential operating expenses to preserve cash for clinical execution.

Key Investment Risks

High liquidity risk with only $4.8 million in cash as of March 31, 2026, requiring near-term dilutive or non-dilutive financing.
Clinical trial execution risk, as the company's valuation is heavily dependent on the success of the Phase 3 OVATION 3 trial.
Pre-revenue status with ongoing operating losses and an accumulated deficit of $425.5 million as of Q1 2026.

Thesis Invalidation Triggers

Failure of the OVATION 3 trial to meet its primary overall survival endpoint during interim or final analyses.
Inability to secure additional funding, leading to a suspension of clinical operations or bankruptcy.
Severe safety signals emerging in the OVATION 3 trial that lead to an FDA clinical hold.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.